Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
14.78
-0.99 (-6.28%)
At close: Aug 20, 2026, 4:00 PM EDT
15.07
+0.29 (1.96%)
After-hours: Aug 20, 2026, 4:21 PM EDT

Monte Rosa Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-161.12-38.63-72.7-135.35-108.5-73.96
Depreciation & Amortization
10.7910.8610.228.323.752.13
Loss (Gain) From Sale of Assets
--0.06--0.02-0.110.02
Loss (Gain) From Sale of Investments
-2.34-2.15-2.95-3.78-1.95-
Stock-Based Compensation
20.5918.8718.1316.6711.665.2
Other Operating Activities
-2.66-2.5-2.1-2.14.810.96
Change in Accounts Receivable
-2.55-4.430.331.9-0.19-
Change in Accounts Payable
1.15-13.716.255.76-0.74-0.71
Change in Unearned Revenue
101.267.5283.3850--
Change in Other Net Operating Assets
10.811.421.4414.81-1.26.99
Operating Cash Flow
-24.07-22.842-43.8-92.47-59.36
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-8.01-4.7-3.99-19.04-12.91-9.73
Sale of Property, Plant & Equipment
---0.060.110.08
Investment in Securities
-308.78-97.13-40.46107.78-206.42-
Investing Cash Flow
-316.79-101.83-44.4588.8-219.22-9.65

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
383.0630.7152.532.6121.45255.79
Other Financing Activities
-21.54-0.3646.3624.88-0.98-21.23
Financing Cash Flow
361.5230.3598.8927.4920.47377.56

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
20.66-94.2896.4472.49-291.22308.55

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-32.08-27.538.01-62.84-105.38-69.1
Free Cash Flow Growth
------
Free Cash Flow Margin
-111.66%-22.23%50.26%---
Free Cash Flow Per Share
-0.35-0.330.51-1.22-2.23-2.76
Levered Free Cash Flow
-74.45-113.0781.97-53.37-72.4-61.29
Unlevered Free Cash Flow
-74.45-113.0781.97-53.37-72.4-61.29

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
110.67-9.1991.472.47-2.136.29
SEC Filings: 10-K · 10-Q